Prognosis of adverse events in patients with suspected chronic heart failure
AssigneeB.R.A.H.M.S GmbH
InventorsJoachim Struck, John GF Cleland
Life of this patent
Estimating the term…
Abstract
The present invention is in the field of clinical diagnostics. Particularly the present invention relates to the prognosis of adverse events in patients with stable chronic heart failure or being suspected of having stable chronic heart failure by determination of the level of Procalcitonin (PCT).
Claims20
A method for determining an enhanced risk of a patient with stable chronic heart failure or suspected of having stable chronic heart failure suffering an adverse event, comprising:
- (a) detecting and quantitating the level of procalcitonin (PCT), or a fragment thereof consisting of amino acids 1 to 116 or 2 to 116 or 3 to 116 of SEQ ID NO:1, in a sample of bodily fluid of said patient, wherein the detection and quantitation comprises a PCT detection assay wherein the sample is contacted with an antibody that specifically binds to PCT to form a detectable PCT:antibody complex, and detecting and quantitating the complex;
- and
- (b) comparing said level of PCT or fragments thereof to a statistically significant predetermined threshold level,
- wherein, when said level of procalcitonin or fragments thereof exceeds said threshold level, said patient is determined to have an enhanced risk of suffering an adverse event.
A method for antibiotic treatment guidance in a patient with stable chronic heart failure or suspected of having stable chronic heart failure, said patient having an increased risk of suffering an adverse event, comprising:
- (a) detecting and quantitating the level of procalcitonin (PCT), or a fragment thereof consisting of amino acids 1 to 116 or 2 to 116 or 3 to 116 of SEQ ID NO:1, in a sample of bodily fluid of said patient, wherein the detection and quantitation comprises a PCT detection assay wherein the sample is contacted with an antibody that specifically binds to PCT to form a detectable PCT:antibody complex, and detecting and quantitating the complex;
- and
- (b) comparing said level of PCT or fragments thereof to a statistically significant predetermined threshold level,
- wherein, when said level of procalcitonin or fragments thereof exceeds said threshold level, said patient is determined to have an enhanced risk of suffering an adverse event, and the need for antibiotic treatment is indicated.
Dependencies are inferred from the claim text.